Literature DB >> 18509687

The ApoC-I content of VLDL particles is associated with plaque size in persons with carotid atherosclerosis.

Ann-Trude With Notø1, Ellisiv Bøgeberg Mathiesen, Jan Brox, Johan Björkegren, John-Bjarne Hansen.   

Abstract

Previous studies have shown that postprandial triglyceride-rich lipoproteins (TRLs) are enriched with apolipoprotein-C-I (apoC-I) in healthy individuals with increased intima-media thickness and in patients with coronary artery disease. The purpose of the present study was to determine apoC-I in TRL in persons with carotid atherosclerosis and its relation to plaque area. A population-based case (n = 42)-control (n = 39) study was conducted in persons with carotid atherosclerosis, assessed by B-mode ultrasound, and healthy controls. VLDL (Sf 20-400) was isolated in the fasting state and 4 h after ingestion of a standard fat meal. In the fasting state, persons with carotid atherosclerosis had increased number of apoC-I per VLDL-particle compared to persons without carotid atherosclerosis (8.6 +/- 5.4 vs. 6.3 +/- 4.2, P = 0.018). Total plaque area increased linearly (P = 0.017) across tertiles of apoC-I per VLDL-particle. In the postprandial state, a similar increase in the number of apoC-I per VLDL-particle occurred in both cases and controls (P < 0.001), but no significant difference was observed between groups. The number of apoC-I per VLDL-particle in the fasting state was accompanied by delayed clearance of TRL in the postprandial state, and associated with cholesterol enrichment of the VLDL-particles. Our findings support the concept that the number of apoC-I per VLDL-particle may be of importance for initiation and progression of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18509687     DOI: 10.1007/s11745-008-3193-2

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.646


  24 in total

1.  Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans.

Authors:  Anders Vik; Ellisiv B Mathiesen; Ann-Trude W Notø; Baldur Sveinbjørnsson; Jan Brox; John-Bjarne Hansen
Journal:  Atherosclerosis       Date:  2006-04-18       Impact factor: 5.162

2.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

Authors:  J E Hixson; D T Vernier
Journal:  J Lipid Res       Date:  1990-03       Impact factor: 5.922

3.  The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study.

Authors:  J W Jukema; A J van Boven; B Groenemeijer; A H Zwinderman; J H Reiber; A V Bruschke; J A Henneman; G P Molhoek; T Bruin; H Jansen; E Gagné; M R Hayden; J J Kastelein
Journal:  Circulation       Date:  1996-10-15       Impact factor: 29.690

4.  Alterations of VLDL composition during alimentary lipemia.

Authors:  J Björkegren; A Hamsten; R W Milne; F Karpe
Journal:  J Lipid Res       Date:  1997-02       Impact factor: 5.922

5.  Postprandial enrichment of remnant lipoproteins with apoC-I in healthy normolipidemic men with early asymptomatic atherosclerosis.

Authors:  Johan Björkegren; Angela Silveira; Susanna Boquist; Rong Tang; Fredrik Karpe; M Gene Bond; Ulf de Faire; Anders Hamsten
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-09-01       Impact factor: 8.311

6.  Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E.

Authors:  M S Weintraub; S Eisenberg; J L Breslow
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

7.  Differences in apolipoprotein and lipid composition between human chylomicron remnants and very low density lipoproteins isolated from fasting and postprandial plasma.

Authors:  J Björkegren; F Karpe; R W Milne; A Hamsten
Journal:  J Lipid Res       Date:  1998-07       Impact factor: 5.922

8.  Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state.

Authors:  J R Patsch; G Miesenböck; T Hopferwieser; V Mühlberger; E Knapp; J K Dunn; A M Gotto; W Patsch
Journal:  Arterioscler Thromb       Date:  1992-11

9.  Familial apolipoprotein E deficiency.

Authors:  E J Schaefer; R E Gregg; G Ghiselli; T M Forte; J M Ordovas; L A Zech; H B Brewer
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

10.  Familial chylomicronemia due to a circulating inhibitor of lipoprotein lipase activity.

Authors:  J D Brunzell; N E Miller; P Alaupovic; R J St Hilaire; C S Wang; D L Sarson; S R Bloom; B Lewis
Journal:  J Lipid Res       Date:  1983-01       Impact factor: 5.922

View more
  4 in total

1.  The apolipoprotein C-I content of very-low-density lipoproteins is associated with fasting triglycerides, postprandial lipemia, and carotid atherosclerosis.

Authors:  John-Bjarne Hansen; José A Fernández; Ann-Trude With Notø; Hiroshi Deguchi; Johan Björkegren; Ellisiv B Mathiesen
Journal:  J Lipids       Date:  2011-07-06

2.  Differentially expressed genes and canonical pathway expression in human atherosclerotic plaques - Tampere Vascular Study.

Authors:  Miska Sulkava; Emma Raitoharju; Mari Levula; Ilkka Seppälä; Leo-Pekka Lyytikäinen; Ari Mennander; Otso Järvinen; Rainer Zeitlin; Juha-Pekka Salenius; Thomas Illig; Norman Klopp; Nina Mononen; Reijo Laaksonen; Mika Kähönen; Niku Oksala; Terho Lehtimäki
Journal:  Sci Rep       Date:  2017-01-27       Impact factor: 4.379

Review 3.  Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism and Beyond.

Authors:  Elena V Fuior; Anca V Gafencu
Journal:  Int J Mol Sci       Date:  2019-11-26       Impact factor: 5.923

Review 4.  Spotlight on very-low-density lipoprotein as a driver of cardiometabolic disorders: Implications for disease progression and mechanistic insights.

Authors:  Hsiang-Chun Lee; Alexander Akhmedov; Chu-Huang Chen
Journal:  Front Cardiovasc Med       Date:  2022-10-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.